Becton Dickinson, BioMedomics Collaborate On Rapid Serology COVID-19 Test

BD and BioMedomics will soon begin distributing a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.

BERLIN, GERMANY - June 06, 2016: BD Vacutainer blood collection tubes
• Source: shutterstock.com

[Editor’s note: This article was updated on 7 April to clarify the regulatory status of the Becton Dickinson/BioMedomics serology COVID-19 test and update the status of the BioGx's rapid COVID-19 test, which runs on Becton Dickinson's automated system.]

Becton Dickinson & Co. is launching a rapid point-of-care serology COVID-19 test developed and manufactured by North Carolina-based BioMedomics, the companies announced on 31 March.

More from Approvals

First At-Home Cervical Cancer Screening Tool Gets FDA Clearance

 
• By 

The US FDA has approved the Teal Wand, the first at-home cervical cancer screening device. Capable of detecting preclinical cancer with 96% accuracy, it will launch in California in June and expand nationwide soon after.

New Treatment For Chronic Facial Pain Could Launch By Fall 2025

 
• By 

NeuroOne is preparing to submit its OneRF Trigeminal Nerve Ablation System to the US FDA for treating trigeminal neuralgia, a chronic facial pain condition. CEO Dave Rosa told Medtech Insight that he expects a possible product launch by fall 2025.

Precision Neuroscience’s FDA Clearance For Core Component Of Brain Implant Expected to Accelerate R&D

 
• By 

Precision’s recent FDA clearance for a core part of its next-generation wireless brain-computer interface system opens the pathway to a safer, more humane BCI for researchers to use compared to higher-risk intracortical arrays, according to BCI expert Naveen Rao.

Edwards Mitral Valve Replacement System SAPIEN M3 Receives CE Mark

 

“We believe [the SAPIEN M3] launch alongside PASCAL and EVOQUE will help support the company’s target of $2bn in transcatheter mitral and tricuspid therapies sales by 2030,” noted analysts from Leerink Partners.

More from Policy & Regulation